RE:RE:Phase 2 Merus founded in 2003 trades at US$58For Merus a confirmed 50% ORR in petosemtamab’s Keytruda combo trial met analysts’ base case expectations, but this was always going to be about the one additional unconfirmed response in the 10 patients evaluated, which would have taken the ORR to 60%., according to one biotech analyst.Truist Securities analysts wrote: “Given how early it is at the data cutoff we think it is likely that this patient will be confirmed with subsequent follow-up."
Currently Mesus is trading at US$59.93 per share +15.86% on limited evaluable patient data.